Preferred Label : Nanatinostat;
NCIt synonyms : HDAC Inhibitor CHR-3996; Histone Deacetylase Inhibitor VRx-3996; WHO 10911; 5-Pyrimidinecarboxamide, 2-((1Alpha,5alpha,6alpha)-6-(((6-fluoro-2-quinolinyl)methyl)amino)-3-azabicyclo(3.1.0)hex-3-yl)-N-hydroxy-;
NCIt related terms : HDAC Inhibitor VRx-3996;
NCIt definition : An orally bioavailable, second-generation hydroxamic acid-based inhibitor of histone
deacetylase (HDAC), with potential antineoplastic activity. Nanatinostat targets and
inhibits HDAC, resulting in an accumulation of highly acetylated histones, the induction
of chromatin remodeling, and the selective transcription of tumor suppressor genes;
these events result in the inhibition of tumor cell division and the induction of
tumor cell apoptosis. This agent may upregulate HSP70 and downregulate anti-apoptotic
Bcl-2 proteins more substantially than some first-generation HDAC inhibitors. HDACs,
upregulated in many tumor cell types, are a family of metalloenzymes responsible for
the deacetylation of chromatin histone proteins.;
UNII : YTL7A418KQ;
InChIKey : QRGHOAATPOLDPF-VQFNDLOPSA-N;
CAS number : 1235859-13-8;
Molecule name : CHR-3996; VRx-3996; VRx 3996; CHR 3996;
Origin ID : C78475;
UMLS CUI : C5139709;
Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
